BASAL CELL CARCINOMA

This study tested a new way to treat basal cell carcinoma, a common skin cancer. Instead of surgery, doctors used a jet-injection device to deliver a drug called ALA into the tumor, then activated it with red light. The trial included 16 adults with small, low-risk BCCs and aimed…

This Phase II trial tested the drug vismodegib in 104 people with advanced basal cell carcinoma, a type of skin cancer that had spread or could not be surgically removed. Participants took a daily capsule until their cancer worsened or side effects became too severe. The study me…

This study looked at the long-term safety of the cancer drug vismodegib in 19 patients with ovarian cancer, basal cell carcinoma, or metastatic colorectal cancer. All participants had previously taken vismodegib in an earlier Genentech trial and were expected to benefit from cont…

This study tested the drug vismodegib given before surgery to people with advanced basal cell carcinoma (a type of skin cancer). The goal was to see if the drug could shrink the tumor enough to allow for a smaller, less invasive surgery. 55 participants took the drug for a period…

This early pilot study tested a new radioactive bandage called CivaDerm on 10 people with common skin cancers (basal cell or squamous cell carcinoma). The bandage delivers radiation directly to the skin surface, aiming to destroy cancer cells while sparing healthy tissue. The stu…

This early study tested a drug called cemiplimab, which helps the immune system attack cancer cells. The drug was injected directly into skin tumors (squamous cell or basal cell carcinoma) for 3 to 12 weeks before planned surgery. The main goal was to check safety and find the ri…

This study tested a new device that delivers targeted radiation to early-stage basal and squamous cell skin cancers. Thirty-six people aged 60 and older received treatment, and researchers tracked how well the cancer was controlled, cosmetic results, and quality of life. The goal…

This study tested whether the drug everolimus can reduce new skin cancers in heart transplant patients who already had skin cancer. 175 participants received either everolimus or standard immunosuppressants. The goal was to see if everolimus lowers the number of new skin tumors n…

This study tested whether taking a daily pill called sonidegib for 12 weeks could shrink basal cell carcinomas in cosmetically sensitive areas like the face. The goal was to make surgery less invasive, reduce scarring, or even avoid surgery altogether by using only a topical crea…

This study tracked 287 people with advanced skin cancer (squamous cell or basal cell) to see how well the drug cemiplimab works outside of a clinical trial. Researchers measured tumor shrinkage, survival, and side effects. The goal was to understand real-world effectiveness and s…

This study tested whether a special microscope (two photon microscopy) can detect leftover basal cell carcinoma during Mohs surgery as accurately as the usual lab method. 135 people having Mohs surgery for skin cancer took part. The goal was to see if the new imaging tool could g…

This study tested whether a daily application of diclofenac gel, a common anti-inflammatory drug, can reverse certain biomarkers in the skin that are linked to non-melanoma skin cancer. Twenty-four adults at risk for skin cancer applied the gel for 30 days, and researchers took s…

This study looked at whether giving people personalized information about their genetic risk for melanoma could encourage them to protect themselves from the sun. Over 2,000 adults received either standard sun safety tips or tailored advice based on their DNA. Researchers then tr…

This study tested a simple photo-based method to measure changes in nose shape and size after skin cancer surgery. Researchers took before-and-after photos of 68 patients who had surgery for common skin cancers. The goal was to see if this photographic approach could be a reliabl…

This completed study looked at the long-term safety of the drug sonidegib in 323 adults with a type of skin cancer called locally advanced basal cell carcinoma. Participants took a daily 200 mg pill, and researchers tracked side effects, serious events, and deaths. The goal was t…